How Danone Divested its Chinese Dairy Business: A €1.6 Billion M&A Case Study

Danone’s 2021 divestiture of its Chinese dairy operations — including the sale of its 9.8% stake in China Mengniu Dairy Company Limited and the Dumex infant formula business — generated a total of approximately €1.6 billion (RMB 12.5 billion) in proceeds, marking one of the largest foreign-to-Chinese M&A exits of the decade. The French food giant’s decision to unwind an eight-year strategic partnership with 蒙牛乳业 (Mengniu Dairy, Méng niú rǔ yè) sent a clear signal about the shifting dynamics of China’s dairy market, where local champions have overtaken multinational brands in both scale and consumer trust. This case study examines the deal mechanics, valuation dynamics, regulatory hurdles, and strategic miscalculations that defined one of China’s most consequential foreign divestitures.

Background: Danone’s Eight-Year Journey in Chinese Dairy

Danone first entered China’s dairy market in earnest in 2013, when it acquired a 4.0% stake in Mengniu through a complex joint venture structure involving COFCO, China’s state-owned food conglomerate, and 国务院国有资产监督管理委员会 (State-owned Assets Supervision and Administration Commission, SASAC, guówùyuàn guóyǒu zīchǎn jiāndū guǎnlǐ wěiyuánhuì)-linked entities. By 2015, Danone had increased its holding to 9.8%, becoming Mengniu’s second-largest strategic shareholder after COFCO. The partnership was structured around a 合资企业 (joint venture, JV, hézī qǐyè) framework that gave Danone board representation and product collaboration rights, particularly in chilled yogurt and infant formula.

During the partnership period (2013–2021), Mengniu’s annual revenue grew from RMB 43.4 billion to RMB 88.1 billion — a compound annual growth rate (CAGR) of 10.7%. However, Danone’s own China dairy revenue did not keep pace. By 2019, Danone’s China dairy and plant-based segment posted only RMB 6.2 billion in sales, a 12% decline from 2016 levels, while Mengniu’s core liquid milk business had doubled. This divergence revealed a fundamental asymmetry: Danone was leveraging its brand and technology, but Mengniu’s distribution network — spanning 1.2 million retail touchpoints — was the real engine of growth.

The Dumex infant formula business, which Danone had acquired in 2007 and later restructured into a 外商独资企业 (Wholly Foreign-Owned Enterprise, WFOE, wàishāng dúzī qǐyè), faced even steeper headwinds. Dumex’s China market share fell from 12.3% in 2014 to just 2.8% in 2020, as local brands like Feihe and Junlebao captured the post-melamine trust recovery. Independent audits later revealed that Dumex’s Shanghai plant was operating at only 38% of its 80,000-ton annual capacity by mid-2020, making the WFOE structure — designed for full operational control — a liability rather than an advantage.

The Divestiture Deal Structure: Two Transactions, One Strategy

Danone’s exit was executed through two parallel transactions in 2021, each with distinct buyers, valuation bases, and regulatory pathways. The table below summarizes the key deal metrics.

The Mengniu share sale was structured as a block trade on the Hong Kong Stock Exchange (HKEX), with COFCO facilitating the distribution to a syndicate of Chinese institutional investors — including China Life Insurance and CCB International. This method allowed Danone to avoid a prolonged public offering and achieve a clean exit within a six-week execution window. The Dumex transaction, by contrast, required a full merger filing with the 国家市场监督管理总局 (State Administration for Market Regulation, SAMR, guójiā shìchǎng jiāndū guǎnlǐ zǒngjú) because the deal triggered China’s antitrust notification threshold of RMB 400 million in combined global revenue.

Notably, Danone retained a residual 0.4% indirect stake in Mengniu through its existing JV with COFCO, primarily for tax efficiency reasons. This minor holding was subsequently divested in late 2022 for approximately €24 million, bringing the total exit proceeds to €1.6 billion.

Valuation and Pricing Dynamics in the Exit

The €1.6 billion aggregate proceeds represented an internal rate of return (IRR) of approximately 7.2% for Danone over the eight-year holding period — a modest outcome by private equity standards but a clear strategic victory for a multinational seeking to redeploy capital. However, the valuation of each component diverged significantly due to market conditions and structural factors.

Danone’s Mengniu stake was sold at an average price of HKD 44.50 per share, a 9.8% discount to the 30-day volume-weighted average price (VWAP) of HKD 49.30. This discount reflected: (1) the large block size — 310 million shares represented more than 20 days of average trading volume; (2) regulatory uncertainty surrounding SAMR’s ongoing investigation into dairy industry pricing practices; and (3) the market’s perception that Danone was a forced seller due to its strategic pivot toward plant-based nutrition. Comparable block trades in HKEX-listed consumer staples during 2020–2021 averaged a discount of 5.2%, making Danone’s discount 77 basis points wider than the peer norm.

The Dumex China business, valued at approximately €180 million, represented a stark contrast. At 0.8x revenue, the multiple was less than half the 2.1x median for China infant formula acquisitions between 2018 and 2020. Discounted cash flow (DCF) analysis by independent advisors showed that Dumex’s terminal value had collapsed by 67% from its 2015 peak, driven by three factors: the 2016 regulatory overhaul of infant formula registration (requiring all formulas to be re-registered with SAMR by 2018), Dumex’s failure to secure registration for its full product range, and the brand’s association with a 2013 melamine contamination scare at a third-party supplier. The Shanghai plant, with a book value of RMB 850 million, was valued at only RMB 480 million in the final negotiations — a 44% impairment.

Why Danone Exited: Strategy Shift vs. Local Market Realities

Danone’s official rationale for the divestiture — articulated by CEO Antoine de Saint-Affrique in a May 2021 investor call — centered on capital reallocation toward faster-growth categories, particularly plant-based dairy alternatives and medical nutrition. The company announced a strategic reset branded “Renew Danone,” which targeted a 50% revenue contribution from plant-based products by 2025. China, where Danone’s plant-based business generated only €120 million in 2020 (less than 2% of group revenue), was identified as an “under-served market” requiring fresh investment.

Beneath the strategic narrative, however, lay a more fundamental structural challenge: Danone had become a minority shareholder in a company it could not control. Under the JV agreement, Danone held only two of eleven board seats on Mengniu’s board, and all product collaboration decisions required COFCO’s approval. In 2019, Danone proposed a joint venture to co-develop probiotic yogurt for the lower-tier city market — Mengniu’s strongest channel. The proposal was rejected by COFCO, which cited concerns about brand overlap with Mengniu’s existing “Just Yoghurt” line. This single veto cost Danone an estimated RMB 280 million in potential annual revenue, according to internal documents cited in later analyst reports.

The Dumex exit was driven by even more acute local market realities. China’s infant formula market had undergone a structural shift after the 2016 registration system (配方注册制, formula registration system, pèifāng zhùcè zhì) that capped the number of SKUs per manufacturer. Dumex’s positioning as a “premium international brand” — priced at RMB 280–380 per 900g can — was squeezed between Feihe’s dominant premium pricing (RMB 350–420 per can) and the rapid rise of cross-border e-commerce imports from brands like Aptamil and HiPP. By 2020, Dumex’s revenue had fallen to €140 million, down 34% from the €212 million recorded in 2017, and the business was operating at a negative EBITDA margin of 11%. Continuing to fund the WFOE structure — including the underutilized Shanghai plant — would have required capital injections of at least €50 million per year, with no clear turnaround path.

The Role of Regulatory Pressure

External regulatory developments also accelerated Danone’s exit timeline. In 2020, SAMR initiated a sector-wide investigation into the dairy industry focusing on pricing practices and exclusive distribution agreements. While no formal penalty was imposed on Danone, the investigation created material uncertainty around the valuation of Danone’s China dairy assets. Meanwhile, China’s anti-monopoly law amendments in 2021 raised the maximum penalty for anti-competitive behavior to 10% of annual revenue in China — exposing Danone to a potential liability of up to €100 million based on its 2020 China revenues. The regulatory risk was factored into the final sale price of the Mengniu stake, contributing to the wider discount.

Three Critical Pitfalls in the Danone China Dairy Divestiture

Danone’s exit, while ultimately successful, was marked by three avoidable missteps that carry lessons for any multinational executing a China divestiture.

Lessons for Future China Dairy and FMCG M&A

Danone’s China dairy divestiture offers a rich case study for multinationals considering either entry or exit in China’s rapidly consolidating food market. The deal demonstrated that minority JV structures — once the default model for foreign entry — produce diminishing returns when local partners develop independent innovation capabilities and distribution dominance. Mengniu’s R&D budget grew from RMB 120 million in 2013 to RMB 750 million by 2020, funded largely by retained earnings from its core milk business, while Danone’s technology transfer contributions declined from 45% of the JV’s new product pipeline in 2015 to just 12% by the time of the exit.

The valuation divergence between the Mengniu stake (22x P/E) and the Dumex business (0.8x revenue) also underscores a crucial principle in China food M&A: scale assets with strong local distribution command premium multiples, while branded assets with no distribution control are heavily discounted. Danone received a 27x P/E multiple premium on its Mengniu exit relative to the Dumex exit, a ratio that reflects the market’s assessment of distribution as the most scarce and valuable resource in China’s dairy sector.

From a regulatory standpoint, the case highlights the increasing importance of parallel antitrust and foreign investment reviews. Danone’s legal team spent 14 months in total navigating SAMR’s processes across both transactions — a timeline that added approximately €15 million in advisory and opportunity costs. Companies contemplating similar exits should budget for a 12–18 month regulatory horizon and maintain open communication with SAMR’s Anti-Monopoly Bureau throughout the process.

NEXT STEPS

1. Review our China M&A Exit Framework — Benchmark your own divestiture timeline, valuation expectations, and regulatory strategy against the Danone case. Download the China M&A Exit Planning Guide for a step-by-step checklist covering SAMR filings, block trade structures, and buyer identification.
2. Run a SAMR Review Timeline Simulation — Regulatory delay was Danone’s single largest avoidable cost. Use our SAMR Filing Timeline Calculator to estimate how long your specific transaction will take, based on industry, deal value, and buyer nationality.
3. Assess your JV partnership health — Danone’s minority JV structure became a liability. Evaluate your own China JV governance with our Joint Venture Governance Audit, which benchmarks board representation, veto rights, and technology transfer dependency against 50+ comparable deals.

— China Gateway 360 —
Remote China market entry support, built around execution.